Beam Therapeutics (BEAM) investor relations material

Executive summary

• Advancing a platform for precision genetic medicines with clinical and preclinical programs targeting hematological and genetic diseases using proprietary base editing technology.

• Lead programs include risto-cel for sickle cell disease, BEAM-302 for AATD, BEAM-304 for PKU, and BEAM-301 for GSDIa.

• Achieved key clinical milestones, including first patient dosed in pivotal BEAM-302 trial for AATD and completion of dosing in BEACON trial for SCD.

• Significant collaborations and licensing agreements with Eli Lilly, Apellis, Pfizer, and Orbital/Bristol-Myers Squibb.

• Ended Q2 2026 with $1.2 billion in cash, supporting operations into mid-2029.

Financial highlights

• License and collaboration revenue was $32.2M for the six months ended June 30, 2026, up from $15.9M year-over-year, driven by a $25M milestone from the Lilly agreement.

• Net loss for the six months ended June 30, 2026 was $217.0M, compared to $210.5M in the prior year period.

• R&D expenses were $199.6M for the first half of 2026; Q2 2026 R&D expenses were $95.1M, down from $101.8M in Q2 2025.

• Cash, cash equivalents, and marketable securities totaled $1.2B as of June 30, 2026, unchanged from December 31, 2025.

• Net loss was $122.7M ($1.18/share) in Q2 2026, compared to $102.1M ($1.00/share) in Q2 2025.

Outlook and guidance

• Cash runway expected to fund operations into mid-2029, including anticipated risto-cel launch and pivotal BEAM-302 development.

• Anticipates increased operating expenses due to clinical development, BLA readiness, and commercial launch preparation.

• Plans to submit a BLA for risto-cel by year-end 2026 and expand pivotal trials for BEAM-302.

• Updated BEAM-302 clinical data to be presented at ERS Congress in September 2026.

• Initial clinical data for BEAM-301 in GSDIa expected in 2026.